<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053092</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000269136</org_study_id>
    <secondary_id>NCRI-LY05</secondary_id>
    <secondary_id>ALLG-LY05</secondary_id>
    <secondary_id>EU-20230</secondary_id>
    <secondary_id>NCRILG-LY05</secondary_id>
    <nct_id>NCT00053092</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma</brief_title>
  <official_title>National Mantle Cell Lymphoma Trial - Phase II Randomized Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Australasian Leukaemia and Lymphoma Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells&#xD;
      and either kill them or deliver cancer-killing substances to them without harming normal&#xD;
      cells. It is not yet known if combination chemotherapy is more effective with or without&#xD;
      rituximab in treating mantle cell lymphoma.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of fludarabine and&#xD;
      cyclophosphamide combined with rituximab to that of fludarabine and cyclophosphamide alone in&#xD;
      treating patients who have mantle cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the response rates in patients with previously untreated mantle cell lymphoma&#xD;
           treated with fludarabine and cyclophosphamide with or without rituximab.&#xD;
&#xD;
        -  Compare the time to disease progression in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the toxicity of these regimens, in terms of adverse event profile, in these&#xD;
           patients.&#xD;
&#xD;
        -  Compare the overall survival of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to 1 of&#xD;
      2 treatment arms:&#xD;
&#xD;
        -  Arm I: Patients receive fludarabine IV* and cyclophosphamide IV* on days 1-3.&#xD;
&#xD;
        -  Arm II: Patients receive rituximab IV on day 1 and fludarabine IV* and cyclophosphamide&#xD;
           IV* on days 2-4.&#xD;
&#xD;
      NOTE: *In both arms, fludarabine and cyclophosphamide may be administered orally instead of&#xD;
      IV.&#xD;
&#xD;
      Treatment repeats every 28 days for 2-8 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 56-82 patients (28-41 per treatment arm) will be accrued for&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to disease progression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed previously untreated mantle cell lymphoma requiring therapy&#xD;
&#xD;
               -  Any stage&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.5 times upper limit of normal (ULN)^*&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN^*&#xD;
&#xD;
          -  Hepatitis B and hepatitis C negative NOTE: *Unless related to lymphoma&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.5 times ULN^* NOTE: *Unless related to lymphoma&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other malignancy within the past 5 years except non-melanoma skin cancer or&#xD;
             curatively resected carcinoma in situ of the cervix&#xD;
&#xD;
          -  No prior psychological illness or condition that would preclude study compliance&#xD;
&#xD;
          -  No known hypersensitivity to murine proteins&#xD;
&#xD;
          -  No concurrent uncontrolled medical conditions&#xD;
&#xD;
          -  No other illness that would severely limit life expectancy&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Rule, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Derriford Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Seymour, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peter MacCallum Cancer Centre, Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>England</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Eve HE, Linch D, Qian W, Ross M, Seymour JF, Smith P, Stevens L, Rule SA. Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study. Leuk Lymphoma. 2009 Feb;50(2):211-5. doi: 10.1080/10428190802688509.</citation>
    <PMID>19197729</PMID>
  </results_reference>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>January 27, 2003</study_first_submitted>
  <study_first_submitted_qc>January 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

